Enwei Pharmaceutical Co., Ltd. Class A

Enwei Pharmaceutical Co., Ltd. Class A

SSZSE:301331
22.40
CNY
-1.01
(-4.31%)
0.36EPS
58.80P/E
2.25BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.91
7.79
7.97
8.68
8.73
8.2
7.64
8.07
8.75
8.15
Basic EPS, GAAP
0.91
1.13
1.06
1.35
1.31
0.8
0.84
0.37
0.5
0.37
Free Cash Flow per Basic Share
1.61
0.54
1.26
0.65
0.63
0.46
-0.49
0.29
0.52
- -
Dividend per Share
0.56
0.08
1.04
0.02
0.59
- -
1.09
0.57
0.2
1.05
Book Value per Share
3.35
5.32
5.2
7.53
8.25
11.11
10.63
10.28
10.43
10
Tangible Book Value per Share
1.18
3.14
3.13
5.57
6.35
9.73
8.23
8.01
8.31
8
Basic Weighted Avg Shares
71
76
78
73
78
84
103
101
103
102
Sales/Revenue/Turnover
559
593
621
634
680
692
785
812
901
829
Operating Margin (%)
19.54
19.99
18.66
19.8
17.72
11.8
11.74
6.23
6.79
5.81
Depreciation Expense
31
35
33
33
30
31
35
46
48
- -
Net Income, GAAP
64
86
83
99
102
68
86
37
52
38
Effective Tax Rate (%)
17.16
14.49
16.6
15.5
14.6
17.18
14.81
19.68
19.04
21.85
Profit Margin (%)
11.52
14.56
13.31
15.57
14.97
9.8
10.99
4.62
5.77
4.56
Working Capital
-35
98
90
175
215
730
577
714
520
661
LT Debt
65
15
- -
- -
- -
- -
- -
187
1
191
Total Equity
312
485
485
587
642
1,153
1,103
1,058
1,073
1,029
Return on Invested Capital (%)
- -
20.57
19.46
20.32
16.84
7.53
7.58
3.36
3.99
- -
Return on Capital (%)
- -
20.9
17.23
18.45
17.07
7.57
7.65
3.36
4.29
- -
Return on Common Equity (%)
- -
25.83
20.15
19.92
16.56
7.55
7.65
3.47
4.88
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
187
12
12
LT Borrowings
- -
190
190
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
103
103
103
Market Capitalization
2,665
2,264
2,247

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
920
856
858
Cash, Cash Equivalents & STI
475
475
481
Accounts Receivable, Net
131
126
126
Inventories
128
131
126
Total Current Liabilities
390
203
197
Payables & Accruals
- -
- -
- -
ST Debt
187
12
12
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
16.4%
1.43%
Free Cash Flow
- -
-63.6%
85.49%
Net Income, GAAP
- -
-4.21%
38.53%
Sales/Revenue/Turnover
- -
7.36%
10.91%
Total Cash Common Dividend
- -
- -
-63.52%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
183
205
172
252
812
2025
196
253
- -
264
901
2026
175
199
191
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.12
0.04
0.16
0.37
2025
0.16
0.23
- -
0.15
0.5
2026
0.12
0.03
0.06
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.69
0.01
0.01
0.57
2025
0.01
0.19
- -
- -
0.2
2026
0.35
0.69
0.01
- -
- -

Company Description

CEO
Yong Jiang Xue
Full Time Employees
1,501
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Changdu China
IPO Date
Sep 21, 2022
Business
Enwei Pharmaceutical Co., Ltd. is a China-based pharmaceutical enterprise engaged in the research, development, manufacturing, and commercialization of proprietary traditional Chinese medicines, chemical drugs, and personal healthcare products. The company develops and markets treatments across several core therapeutic categories through established brand lines, including Jieeryin, Haowayou, Likeshu, Zhongzhou, and Koubao. Its product portfolio comprises gynecological pharmaceuticals and feminine hygiene products, such as Jie'er Yin cleansing lotions, effervescent tablets, ointments, and miconazole nitrate vaginal soft capsules; pediatric and gastrointestinal medications, including Shanmai Jianpi oral liquid, Huaji oral liquid, and Jian'er pills; respiratory, cold, and pain relief treatments, including compound paracetamol and amantadine hydrochloride tablets, paracetamol and ibuprofen tablets, compound yinqiao aminomin capsules, antiviral oral liquid, and Jiawei Huoxiang Zhengqi mixture; and consumer health and intimate care products, including antimicrobial washes, skin care ointments, and oral hygiene solutions. The company conducts its manufacturing activities through specialized subsidiaries, notably Sichuan Enwei Pharmaceutical Co., Ltd., operating modern production lines that cover multiple formulations such as lotions, ointments, oral liquids, tablets, granules, and capsules. Enwei Pharmaceutical markets and distributes its products throughout mainland China via retail pharmacy chains, hospitals, and rapidly growing third-party and direct-to-consumer e-commerce channels, employing a hybrid model of in-house marketing personnel and third-party distribution partners. In recent strategic developments, Enwei Pharmaceutical significantly expanded its product portfolio through the restructuring and acquisition of Henan Xinxin Pharmaceutical Co., Ltd., securing 125 proprietary traditional Chinese medicine product approval licenses across respiratory, hepatobiliary, and tonifying therapeutic areas. Following this integration, the company initiated the commercial revival and outsourced manufacturing of priority acquired products, including antiviral oral liquid, qingre jiedu oral liquid, qinggan lidan oral liquid, and shengmai yin. Additionally, the company acquired the Marketing Authorization Holder rights for paracetamol and ibuprofen tablets to strengthen its respiratory and analgesic segment, scaled its dedicated pharmaceutical e-commerce operational division, and accelerated pipeline rollouts for traditional preparations including Wuji Baifeng pills. Enwei Pharmaceutical Co., Ltd. was founded in 1986 and is headquartered in Chengdu, Sichuan Province, China.